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Background: At present, there are no specific nationwide epidemiological studies representing the 
whole Italian population. This study is aimed at describing the epidemiological and economic burden 
that HCV will generate in the next few years in Italy. Furthermore, the impact that future anti-HCV 
treatments may have on the burden of disease was considered. This analysis was developed for the 
period 2012–2030 from the perspective of the Italian National Health Service (NHS). 
Methods: A published system dynamic model was adapted for Italy in order to quantify the HCV-
infected population in terms of disease progression and the associated costs from 1950 to 2030. The 
model structure was based on transition probabilities reflecting the natural  history of the disease. 
In order to estimate the efficacy of current anti-HCV treatment strategies for genotypes 1 and 4, 
the sustained virological response (SVR) rate in registration clinical trials for both boceprevir and 
telaprevir was estimated. It was assumed that the efficacy for patients treated with peginterferon + 
ribavirin was equal to the placebo arm of a randomized clinical trial (RCT) relating to boceprevir 
and telaprevir. For genotypes 2/3 patients it was assumed that treatment efficacy with dual therapy 
was equal to a SVR rate from the literature. According to the aim of this study, only direct health 
care costs (hospital admissions, drugs, treatment, and care of patients) incurred by the Italian 
NHS have been included in the model. Costs have been extrapolated using the published scientific 
literature available in Italy and actualized with the 2012 ISTAT (Istituto Nazionale di Statistica) 
Price Index system for monetary revaluation. Three different scenarios were assumed in order to 
evaluate the impact of future anti-HCV treatments on the burden of disease.
Results: Overall, in Italy, 1.2 million infected subjects were estimated in 2012. Of these, 
about 211,000 patients were diagnosed, while only about 11,800 subjects were actually 
being treated with anti-HCV drugs. A reduction of health care costs is associated with a 
prevalence decrease. Indeed, once the spending peak is reached during this decade (about 
€527 million), the model predicts a cost reduction in the following 18 years. In 2030, based 
on the more effective treatments currently available, the direct health care cost associated 
with the management of HCV patients may reach €346 million (−34.3% compared to 2012). 
The first scenario (new treatment in 2015 with SVR =90% and same number of treated 
patients) was associated with a significant reduction in HCV-induced clinical consequences 
(prevalence =−3%) and a decrease in direct health care expenses, corresponding to €11.1 mil-
lion. The second scenario (increase in treated patients to 12,790) produced an incremental 
cost reduction of €7.3 million, reaching a net decrease equal to €18.4 million. In the third 
scenario (treated patients =16,770), a higher net direct health care cost decrease versus the 
base-case (€44.0 million) was estimated.
Conclusion: Our model showed that the introduction of new treatments that are more effective 
could result in a quasi-eradication of HCV, with a very strong reduction in prevalence.
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Methods
A published system dynamic model14 was adapted for 
Italy in order to quantify the HCV-infected population 
in terms of disease progression and the associated costs 
from 1950–2030. The model structure was based on 
transition probabilities reflecting the natural history of 
the disease (Figure 1). The time horizon was settled in 
19 years (2012–2030) and a lag transition of 1 year was 
considered. Transition probabilities have been associated 
with cost variables of each pathological state and related 
treatment able to predict - in addition to the epidemiologi-
cal burden - the economic cost incurred by NHS. Further 
details on the methods used are reported in the appendix 
of a previous study.14
Epidemiological data
The model predicted the future projection of epidemiologi-
cal effects, starting from historical data. Data reported by 
the United Nations in terms of a historical series in the 
residential Italian population from 1950 to 2012 were used.15 
In addition to this, the death rates of the Italian population16 
were taken into account. Therefore, a projection of effects 
between 2008 and 2030 was calculated on the basis of his-
torical demographic data in which the age of the population 
was grouped into 5-year clusters.
The model assumed an incidence rate equal to 0.016%. 
Furthermore, the predictive model included a redistribu-
tion of prevalence data by age and sex. With reference 
to this parameter, an American model was adjusted 
to the Italian context using national literature data.17,18 
Hence, the model was calibrated by comparing the output 
trend with the age-specific prevalence of HCV infection 
(Figure 2).
The number of diagnosed and treated patients in Italy 
is considerably lower than in the US. Based on published 
data, it was assumed that in Italy, only 8% of chronic 
HCV patients are currently treated in clinical centers,19 
and among these diagnosed patients, only 20% are treated 
with dual or triple therapy.20 Finally, patients were divided 
by genotypes according to national epidemiological 
data21,22 where a prevalence of 56%, 30%, 10%, and 5% 
in terms of genotypes 1, 2, 3, and 4, respectively, was 
estimated.
Treatment efficacy
In order to estimate the efficacy of current anti-HCV 
treatment strategies in genotype 1 patients, the sustained 
Background
In 2010, the World Health Organization (WHO) recognized 
that hepatitis C virus (HCV) is a major global public health 
problem.1 It is estimated that about 3% of the world’s popula-
tion is HCV positive.2 The prevalence of the disease varies 
around the world.
According to the study conducted by the European Centre 
for Disease Prevention and Control (ECDC), Italy has the 
highest number of HCV positive subjects in Europe and the 
highest death rate from hepatocellular carcinoma (HCC) 
and cirrhosis.3
In fact, chronic HCV infection is a primary cause of cir-
rhosis, HCC, and liver transplantation.4 HCV is currently 
the major etiologic agent in patients needing medical assis-
tance due to chronic hepatic diseases5,6 and, as in the rest of 
the world, is the most common cause of liver transplantation.7 
However, despite being the only therapeutic treatment for ter-
minal liver disease, transplantation does not treat HCV infec-
tion, and recurrence may take place after transplantation.8
At present, there are no specific nationwide epidemio-
logical studies representing the whole Italian population. 
However, HCV prevalence has been evaluated in some local 
or regional studies.9 HCV ribonucleic acid prevalence is nor-
mally around 3% (with an average value of about 6%–10% 
in a 1940–1949 birth cohort); it is usually lower than 2% 
(mean: 1.6%) in people born in 1950–1959 and tends to 
decrease in younger people.10 In addition to age correlation, 
the North–South geographical gradient generates a remark-
able epidemiological variability. In fact, prevalence is higher 
in southern regions (7.3%) in comparison to central (6.1%) 
and northern ones (1.6%).11
It is clear that in future, society and the health service will 
have to face the complications of HCV-induced pathologies, 
involving a growing demand in liver transplantations and 
HCC treatments.12 The costs of viral hepatitis are high and 
tend to increase according to disease severity. In addition to 
the direct costs incurred for disease management, there are 
indirect costs linked to the loss of productivity due to dis-
ability and premature death in patients suffering from the 
chronic HCV infections.13
This study is aimed at describing the epidemiological 
and economic burden that HCV will generate in the next 
few years in Italy. Furthermore, the impact that future 
anti-HCV treatments may have on the burden of disease 
was considered. The analysis has been developed for the 
period 2012–2030 from the perspective of the Italian National 
Health Service (NHS).
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 virological response (SVR) rate was estimated in registration 
trials for both boceprevir (70.0% and 64.4% in treatment-
naïve and treatment-experienced patients, respectively) 
and  telaprevir (70.0% in treatment-naïve and 67.4% in 
treatment- experienced patients).23–26 It was assumed that 
the efficacy of peginterferon + ribavirin in genotype 1 
patients was equal to the placebo arm of a randomized clini-
cal trial (RCT) relating to boceprevir (SVR rate of 36.6% 
and 24.2% in treatment- naïve and treatment-experienced 
patients, respectively).23,24 It was assumed that in genotypes 
2/3, treatment efficacy with dual therapy was equal to a 
SVR rate of 65% in treatment-naïve patients27 and 59% in 
treatment-experienced ones.28 Finally, it was assumed that 
the SVR rate for genotype 4 was comparable to that for 
genotype 1 in this model.
In the base-case, the model assumed that only 10% of 
genotype 1 patients eligible for treatment in Italy were treated 
with boceprevir and telaprevir. The remaining diagnosed 
patients were assumed to be treated with peginterferon + 
ribavirin or kept under observation.
Cost data
According to the aim of this study, only direct health care 
costs (hospital admissions, drugs, treatment, and care of 
patients) incurred by the Italian NHS have been included 
in the model. Table 1 reports direct cost data associated 
with each health condition. Costs have been extrapolated 
using the published scientific literature available in Italy 
and actualized with the 2012 ISTAT (Istituto Nazionale di 
Statistica) Price Index system for monetary revaluation.29 
Furthermore, transplantation costs have been estimated 
using the surgery cost calculated through the Diagnosis 
Related Group (DRG) reimbursement tariffs30 to which the 
treatment cost following the first year of transplantation has 
been added.10,31,32
In addition to the above reported costs, in chronic HCV 
hepatitis and compensated cirrhosis patients, costs associated 
with dual and triple therapy have been estimated. Table 1 
reports input data to estimate treatment costs with dual and 
triple therapy. The weekly cost of dual therapy has been 
estimated on the basis of the spending data published in the 
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Figure 2 Prevalence by sex and age in italy, 2012.
Note: Data comparison of literature and model estimate taken from ansaldi et al17 and Cozzolongo et al.18
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literature.31 For triple therapy, ex-factory prices of boceprevir 
and telaprevir published in the Official Gazette of the Italian 
Republic33 were used. This price was multiplied by the esti-
mated average number of treatment weeks as given by the 
European Medicine Agency (EMA) guidelines.34,35
Scenario analysis
The model included three future scenarios and a base-case. 
The base-case scenario assumed that all eligible patients 
were treated with peginterferon + ribavirin, and that 10% of 
the genotype 1 patients were treated with the most recent 
protease inhibitors (50% with telaprevir and 50% with 
boceprevir). In this base-case scenario, it was assumed that 
no new treatments will be available in Italy, and therefore, 
the treatment of patients suffering from chronic HCV is not 
substantially changed. The base-case scenario has been com-
pared with three alternative scenarios, each one including dif-
ferent assumptions, as indicated in Table 2. The assumptions 
of each scenario have been based on the expert opinion of 
a clinical board composed by the authors of this work. The 
scenarios aim to evaluate the epidemiological and economic 
impact that the new anti-HCV treatments might have from the 
 Italian NHS perspective. In all scenarios, it has been assumed 
that the cost of the new treatment is comparable to protease 
inhibitor therapy (conservative assumption).
Sensitivity analysis
Sensitivity analysis is recommended any time there 
is  uncertainty.36 In order to verify the uncertainty of 
the model results, a probabilistic sensitivity analysis 
(PSA)37 was  performed. PSA provides a useful tech-
nique to quantify the level of confidence of a decision 
maker in drawing the conclusions of an economic evalu-
ation.37 At each model parameter, a probability distribu-
tion (Table 3) was assigned to perform 5,000 Monte Carlo 
simulations in order to test the robustness of the results 
and define a 95% confidence interval (CI) for the data.
Results
Overall, in Italy, 1.2 million infected subjects were estimated 
in 2012. Of these, about 11,800 subjects are actually being 
treated with anti-HCV drugs.
The virus peak of chronic HCV prevalence was reached 
during the 1990s, with the number of infected subjects 
exceeding 1.8 million (Figure 3A). Thereafter, it is estimated 
that the total prevalence will decrease until 2030 due to the 
effect of new treatments currently being used in Italy. In 
fact, observing the prevalence decrease by HCV sequelae, it 
is possible to note that cirrhotic patients show a larger drop 
in prevalence, while more serious pathologies, like HCC 
and liver transplantation, initially increase and then slightly 
decrease (Figure 3B).
Table 1 Direct health care costs associated with health conditions 
considered in the analysis
Direct annual costs Initial  
value
Actualized 
cost
Reference
Chronic hepatitis €246 €288 10,31,32
Compensated cirrhosis €347 €407 10,31,32
Decompensated cirrhosis €5,466 €6,409 10,31,32
Carcinoma €6,075 €7,124 10,31,32
Transplantation (surgery) €80,199 €80,199 30
Transplantation 
(1st year treatment)
€4,729 €4,729 10,31,32
Drug costs Weekly 
cost
Treatment 
(number of 
weeks)
Reference
Peginterferone-2a + ribavirin €283 48 20
Peginterferone-2b + ribavirin €261 48 20
Boceprevir €643 35 33,34
Telaprevir €1,880 12 33,35
Table 2 Model parameters by analysis scenario
Parameter Scenario 1 Scenario 2 Scenario 3
initiation of new treatment 2015 2015 2015
Patients eligible for treatment (genotypes) g1 g1–g4 g1–g4
Fibrosis status (Metavir score) $F2 $F2 $F2
Rate of eligible patients being treated 60% 80% 90%
Rate of patients treated with the new treatment 10% (2015), 
15% (2016), 
25% (2018)
10% (2015), 
15% (2016), 
25% (2018)
15% (2015), 
25% (2016), 
35% (2018)
sVR attributed to the new treatment 90% (naïve) 
80% (experienced)
90% (naïve) 
80% (experienced)
90% (naïve) 
80% (experienced)
Compliance to new treatment 80% 80% 90%
The number of treated patients is Constant over time 
(n=11,860)
increased 
(from 11,860–12,790)
increased 
(from 11,860–16,770)
Abbreviations: F, fibrosis grade; G, genotype; n, number of subjects; SVR, sustained virological response.
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A reduction in health care costs is of course associated 
with a decrease in prevalence. Indeed, once the spending 
peak is reached during this decade (about €527 million), the 
model predicts a spending reduction in the following 18 years 
(Figure 3A). In 2030, due to the more effective treatments 
currently available, the direct health care spending associated 
with the management of patients suffering from HCV may 
reach €346 million (−34.3% compared to 2012).
The first scenario was associated with a significant reduc-
tion in HCV-induced clinical consequences (prevalence 
of −3%) and a decrease in direct health care expenses 
corresponding to €11.1 million (95% CI: −€7.1 to −€15.0) 
(Table 4 and Figure 4). The second scenario produced an 
incremental cost reduction of €7.3 million, reaching a net 
decrease equal to €18.3 million (95% CI: −€16.2 to −€20.5). 
In the third scenario, a higher net direct health care cost 
decrease versus the base-case (€44.0 million, 95% CI: −€42.2 
to −€45.8) was estimated.
Moreover, the second scenario almost doubled the reduc-
tion of HCV prevalence (−5%), as well as the number of 
prevented deaths (+7.5% versus the first scenario). However, 
the third scenario estimated −11% in terms of prevalence 
during the considered follow-up period and a higher number 
of prevented deaths (+33.9% versus the first scenario and 
+24.5% versus the second scenario). Although conservative, 
all scenarios can be deemed reliable and realistic from the 
Italian NHS perspective.
Discussion
Chronic HCV infection is a pathological condition with 
high economic and social impacts worldwide, particularly 
in Italy, in which the prevalence is around 2.0%–3.5%.17,18 
The Italian situation is peculiar and ECDC epidemiologi-
cal analysis shows that this is the highest prevalence rate 
in Europe.3 Unfortunately, these are only estimates and not 
collected data.
Our study was aimed at dealing with the lack of reliable 
information on the Italian burden of HCV-induced diseases. 
Available estimates on HCV pathologies and the expected 
epidemiological trend are very limited, if existing at all. 
Furthermore, the objective was to provide decision makers 
with fundamental information for reflection and discussion, 
in order to allow them to plan the implementation of rational 
and economically sustainable actions aimed at the control 
and eradication of the infection.
Following its historical evolution, viral HCV infection 
peaked in the 1990s and decreased in the new millen-
nium. From 2012, the model predicted a steady decrease in 
prevalence that can be attributed to new available treatments. 
Table 3 Probabilistic sensitivity analysis parameter (range and 
distribution)
Range Distribution Reference
Min Max
Epidemiological and efficacy parameter
Prevalence rate: male 2.0% 3.5% BETa 17,18
Prevalence rate: female 2.0% 3.5% BETa 17,18
incidence rate 0.010% 0.020% BETa
sVR base-case g1/g4 24.0% 37.0% BETa 23–26
sVR base-case g2/g3 59.0% 65.0% BETa 23–26
Annual cost
Chronic hepatitis €231 €346 gaMMa 10,31,32
Compensated cirrhosis €325 €489 gaMMa 10,31,32
Decompensated  
cirrhosis
€5,125 €7,691 gaMMa 10,31,32
Carcinoma €5,699 €8,548 gaMMa 10,31,32
Transplantation  
(surgery)
€72,175 €88,221 gaMMa 30
Transplantation  
(1st year treatment)
€3,784 €5,675 gaMMa 10,31,32
Abbreviations: g, genotype; sVR, sustained virological response; Min, minimum; 
Max, maximum. 
2,000 350,000
F1
F2
F3
HCC
Decomp cirrhosis
Cirrhosis – F4
Chronic HCV (F0)
Liver transplant
300,000
250,000
200,000
150,000
100,000
50,000
0
20
13
20
12
20
15
20
14
20
16
20
17
20
18
20
20
20
22
20
21
YearYear
20
23
20
24
20
25
20
26
20
27
20
28
20
29
20
30
20
19
A B
Prevalence Health care cost
E
u
ro
 (
M
)
€600
€500
€400
€300
€200
€100
€0
1,800
1,600
1,400
1,200
1,000
800
400
600
P
re
va
le
n
ce
 (
T
h
o
u
sa
n
d
)
P
re
va
le
n
ce
200
0
19
50
19
70
19
60
19
90
19
80
20
00
20
10
20
20
20
30
Figure 3 Prevalence estimate and yearly health care costs: italy base-case.
Notes: (A) Total prevalence and health care costs: italy 1950–2030; (B) hCV sequelae and total prevalence: italy 2012–2030.
Abbreviations: HCC, hepatocellular carcinoma; HCV, hepatitis C virus; F, fibrosis grade; Decomp, decompensated. 
ClinicoEconomics and Outcomes Research 2014:6submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
308
Mennini et al
A further thrust to the eradication of this disease could be 
given by the use of new and more effective treatments that, 
on one hand, would allow us to increase the typology of 
patients to be treated, and on the other, increase the number 
of those actually treated. This would allow us to reach two 
primary objectives for the NHS: to reduce the impact of 
disease transmission and obtain economic benefits associ-
ated with the prevention of dramatically expensive disease 
complications such as decompensated cirrhosis, HCC, and 
liver transplantation.
Despite being conservative, the analyzed scenarios have 
allowed us to evaluate the epidemiological and economic 
impacts that the new anti-HCV treatments may have from 
the Italian NHS perspective. The opportunity to treat patients 
with a higher eligibility rate and therapy compliance, espe-
cially at an early stage, is not only ethically indisputable, 
but also economically efficient (scenario 3 allows better 
epidemiological and economic performance).
As of today, there are neither national studies that allow us 
to evaluate the economic burden of HCV-induced pathologies, 
Table 4 Results by analysis scenario and base-case comparison
Scenario 1 2012 2030 scenario 1 2030 scenario 1 vs  
2012
2030 scenario 1 vs  
2030 base-case
Prevalence (n) 1,242,682 566,521 −676,161 −15,688
 95% Ci (min, max) 917,150 1,568,213 402,842 730,200 −514,309 −838,013 −9,336 −22,039
health care cost (€million) €527.0 €334.9 −€192.0 −€11.1
 95% Ci (min, max) €388 €666 €232 €438 −€156 −€228 −€7.1 −€15.0
Scenario 2 2012 2030 scenario 2 2030 scenario 2 vs  
2012
2030 scenario 2 vs  
2030 base-case
Prevalence (n) 1,242,682 556,323 −686,358 −25,885
 95% Ci (min, max) 917,150 1,568,213 389,842 722,805 −527,308 −845,408 −22,336 −29,434
health care costs (€million) €527.0 €327.6 −€199.3 −€18.3
 95% Ci (min, max) €388 €666 €223 €432 −€165 −€234 −€16.2 −€20.5
Scenario 3 2012 2030 scenario 3 2030 scenario 3 vs  
2012
2030 scenario 3 vs  
2030 base-case
Prevalence (n) 1,242,682 520,909 −721,772 −61,299
 95% Ci (min, max) 917,150 1,568,213 348,154 693,665 −568,996 −874,548 −64,024 −58,574
health care costs (€million) €527.0 €302.0 −€224.9 −€44.0
 95% Ci (min, max) €388 €666 €194 €410 −€194 −€256 −€42.2 −€45.8
Abbreviations: CI, confidence interval; n, number of subjects; min, minimum; max, maximum; vs, versus.
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nor studies able to predict their evolution. However, a recent 
work of Razavi et al14 in 2013, from which this study 
derives, has allowed us to predict the infection evolution of 
HCV-induced pathologies in the US. In accordance with the 
American study, in our country, HCV prevalence is bound 
to decrease, even if with very different age dynamics. The 
extent of this decrease will be determined by the scenario that 
future anti-HCV treatments will follow and by the choices 
of decision makers.
The model has limitations. First of all, epidemiological 
parameters need to be taken into account. If the shortage of 
national data makes reliability of results difficult, a model and 
a systematized method of information, like the one presented 
in this study, allows us to obtain estimates that are as reliable 
as possible. Secondly, there is a difficulty in considering 
further variables that may potentially influence the Italian 
demographic and social dynamics. Indeed, the model does 
not take into account any changes in the social behavior of 
the population, and nor does it consider the possible influ-
ence of migratory dynamics or the possible variation of risk 
factors influencing viral transmission (ie, injection drug use, 
accidental needlestick injuries, minor nosocomial surgical 
procedures, acupuncture, tattooing, or piercing). Finally, no 
monitoring or side effects were considered for anti-HCV 
drugs, which may cause underestimation of the savings 
attributable to a better safety of new drugs.
In conclusion, the analysis showed that the introduction 
of new treatments that are more effective could result in a 
quasi-eradication of HCV, with a very strong reduction in 
prevalence. In addition, a large number of lives could be saved 
from HCV-related deaths accompanied by a large reduction 
in the number of liver transplantations.
In addition, the model suggests that the potential of new 
treatments produces significant consequences not only in 
greater efficiency, but also in terms of security and shorter 
treatment durations.
All this, according to the logic of economic evaluations, 
represents a valuable tool for future health policies relating to 
HCV, and the benefits to health and economics that the new 
treatments will cause can be ensured in the near future.
We must not forget the great impact in terms of reducing 
indirect costs (both in terms of reduction of lost productivity, 
and above all, in terms of the impact on social security and 
social expenditure, which in Italy is financed by means of 
public expenditure).
This study does not have the pretension of being or 
creating a perfect model of epidemiological projection. 
The objective of this study was to supply data and carefully 
consider a dialectical confrontation among different 
professionals involved in the management of patients with 
HCV-induced chronic infection, and to suggest a valuable 
tool for future health policy strategy.
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